Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IMVT
stocks logo

IMVT

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
--
--
-0.686
+14.26%
--
--
-0.710
-4.05%
--
--
-0.726
-4.53%
Estimates Revision
Stock Price
Go Up
up Image
+17.56%
In Past 3 Month
10 Analyst Rating
up Image0
Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 41.67 USD with a low forecast of 18.00 USD and a high forecast of 58.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
2 Hold
0 Sell
Strong Buy
up Image0
Current: 17.810
sliders
Low
18.00
Averages
41.67
High
58.00
up Image0
Current: 17.810
sliders
Low
18.00
Averages
41.67
High
58.00
Goldman Sachs
Neutral
maintain
$18
2025-07-10
Reason
Goldman Sachs
Price Target
$18
2025-07-10
maintain
Neutral
Reason
Goldman Sachs resumed coverage of Immunovant with a Neutral rating and $18 price target. The firm sees limited downside but also a challenging regulatory backdrop for the company.
H.C. Wainwright
Buy
downgrade
$51 -> $35
2025-05-30
Reason
H.C. Wainwright
Price Target
$51 -> $35
2025-05-30
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Immunovant to $35 from $51 and keeps a Buy rating on the shares. The target cut reflects the company's data readouts in 2027, with an expected potential launch in 2028.
UBS
Colin Bristow
Strong Buy
to
Hold
Downgrades
$38 → $17
2025-04-22
Reason
UBS
Colin Bristow
Price Target
$38 → $17
2025-04-22
Downgrades
Strong Buy
to
Hold
Reason
UBS downgraded Immunovant to Neutral from Buy with a price target of $17, down from $38.
B of A Securities
Jason Gerberry
Strong Buy
Maintains
$38 → $33
2025-03-20
Reason
B of A Securities
Jason Gerberry
Price Target
$38 → $33
2025-03-20
Maintains
Strong Buy
Reason
Guggenheim
Yatin Suneja
Strong Buy
Reiterates
n/a
2025-03-20
Reason
Guggenheim
Yatin Suneja
Price Target
n/a
2025-03-20
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$51
2025-03-19
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$51
2025-03-19
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunovant Inc (IMVT.O) is -6.13, compared to its 5-year average forward P/E of -11.95. For a more detailed relative valuation and DCF analysis to assess Immunovant Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.95
Current PE
-6.13
Overvalued PE
-2.92
Undervalued PE
-20.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.78
Current EV/EBITDA
-5.14
Overvalued EV/EBITDA
-0.98
Undervalued EV/EBITDA
-18.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.21
Current PS
333.46
Overvalued PS
61.59
Undervalued PS
-41.17

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 133.13% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

IMVT News & Events

Events Timeline

(ET)
2025-05-29
07:08:08
Immunovant sees cash runway through GD readout expected in 2027
select
2025-05-29
07:07:16
Immunovant reports Q4 EPS (64c), consensus (72c)
select
2025-04-21 (ET)
2025-04-21
07:05:46
Immunovant appoints Eric Venker as CEO, Girao as CFO
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
06-02TipRanks
3 Best Stocks to Buy Now, 6/2/2025, According to Top Analysts

  • Top Stock Picks: Analysts have identified three stocks as Strong Buys: Immunovant (IMVT) with a potential upside of 154%, Biohaven Ltd. (BHVN) with an upside of 305%, and DraftKings (DKNG) with an upside of 52.62%.

  • Analyst Ratings: All selected stocks have received recent Buy ratings from top analysts, indicating confidence in their future performance and growth potential.

Preview
7.0
05-30PRnewswire
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm

  • Investigation Announcement: Robbins Geller Rudman & Dowd LLP is investigating potential breaches of fiduciary duty by Immunovant, Inc. directors and Roivant Sciences Ltd. related to a private placement transaction where Roivant purchased shares at a significant discount, benefiting them by nearly $60 million.

  • Company Background: Immunovant is a clinical-stage immunology company that merged with Health Sciences Acquisitions Corporation in December 2019, and Roivant has maintained majority control over Immunovant's stock since the merger.

Preview
9.5
05-29Newsfilter
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

  • Management Focus: Immunovant's new leadership is prioritizing rapid clinical execution for IMVT-1402 across six indications, with registrational studies in Graves' disease and Sjögren's disease expected to begin in summer 2025.

  • Financial Overview: The company reported a net loss of $106.4 million for Q4 2025, with a cash balance of approximately $714 million, providing sufficient funds for ongoing clinical trials until the anticipated Graves' disease readout in 2027.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Immunovant Inc (IMVT) stock price today?

The current price of IMVT is 17.81 USD — it has increased 1.83 % in the last trading day.

arrow icon

What is Immunovant Inc (IMVT)'s business?

Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

arrow icon

What is the price predicton of IMVT Stock?

Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 41.67 USD with a low forecast of 18.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Immunovant Inc (IMVT)'s revenue for the last quarter?

Immunovant Inc revenue for the last quarter amounts to -113.83M USD, increased 40.73 % YoY.

arrow icon

What is Immunovant Inc (IMVT)'s earnings per share (EPS) for the last quarter?

Immunovant Inc. EPS for the last quarter amounts to -110838000.00 USD, increased 85.20 % YoY.

arrow icon

What changes have occurred in the market's expectations for Immunovant Inc (IMVT)'s fundamentals?

The market is revising No Change the revenue expectations for IMVT for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 17.56%.
arrow icon

How many employees does Immunovant Inc (IMVT). have?

Immunovant Inc (IMVT) has 362 emplpoyees as of July 17 2025.

arrow icon

What is Immunovant Inc (IMVT) market cap?

Today IMVT has the market capitalization of 3.05B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free